The American College of Cardiology announced the lineup of late-breaking clinical trials for its upcoming annual meeting in Washington, DC. The opening session will include the most eagerly anticipated trials– the main results of Symplicity HTN-3 and the comparison of Corevalve and surgery in high risk patients. Subsequent sessions will include several phase 3 trials of PCSK9 inhibitors. Here is the complete list of trials:
…
Click here to read the full post on Forbes.
Speak Your Mind